A detailed history of Asset Management Group, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Asset Management Group, Inc. holds 2,484 shares of GILD stock, worth $222,963. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,484
Holding current value
$222,963
% of portfolio
0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$66.59 - $83.99 $165,409 - $208,631
2,484 New
2,484 $208,000
Q2 2023

Aug 14, 2023

BUY
$76.01 - $86.7 $2,204 - $2,514
29 Added 0.98%
2,999 $231,000
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $2,087 - $2,378
27 Added 0.92%
2,970 $246,000
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $183,407 - $263,310
2,943 New
2,943 $252,000
Q2 2022

Aug 15, 2022

BUY
$57.72 - $65.01 $1,962 - $2,210
34 Added 0.98%
3,492 $216,000
Q1 2022

May 16, 2022

BUY
$57.92 - $72.58 $2,432 - $3,048
42 Added 1.23%
3,458 $206,000
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $2,141 - $2,430
33 Added 0.98%
3,416 $248,000
Q3 2021

Nov 15, 2021

BUY
$67.69 - $73.03 $1,963 - $2,117
29 Added 0.86%
3,383 $236,000
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $2,094 - $2,288
33 Added 0.99%
3,354 $231,000
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $199,260 - $227,355
3,321 New
3,321 $215,000
Q4 2020

Feb 16, 2021

SELL
$56.65 - $64.55 $530,697 - $604,704
-9,368 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$62.1 - $78.08 $19,188 - $24,126
309 Added 3.41%
9,368 $592,000
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $20,399 - $23,688
282 Added 3.21%
9,059 $697,000
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $549,703 - $704,090
8,777 New
8,777 $656,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Asset Management Group, Inc. Portfolio

Follow Asset Management Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management Group, Inc. with notifications on news.